论文部分内容阅读
结肠直肠癌(colorectal cancer,CRC)是全球最常见的恶性肿瘤之一,约25%的病人在初诊时已转移[1];即使早期发现并接受根治的病人,也有约三分之一最终会出现转移复发,这些转移性结肠直肠癌(metastatic CRC,m CRC)病人的5年生存率常低于50%[2]。近年来分子靶向药物的出现显著改善了m CRC病人的预后,其生存期从单纯化疗的20个月提高到近30个月[1]。迄今为止,已有多个分子靶向药物被美国食品和药品管理局(Food and Drug Administration,FDA)批准使用,包括贝伐珠单抗、西妥昔单抗和帕尼单抗等。现就其各自不同的抗肿瘤作用和临床疗效作一综述。
Colorectal cancer (CRC) is one of the most common malignancies in the world, with about 25% of patients having metastases at the time of first visit [1]; about one-third of patients with early detection and cure will eventually With metastatic recurrence, the 5-year survival of these patients with metastatic CRC (mCRC) is often less than 50% 2. In recent years, the emergence of molecular targeted drugs has significantly improved the prognosis of patients with m CRC, its survival increased from 20 months of chemotherapy alone to nearly 30 months [1]. To date, several molecularly targeted drugs have been approved for use by the Food and Drug Administration (FDA), including bevacizumab, cetuximab and panitumumab. Now on their different anti-tumor effect and clinical efficacy are reviewed.